2,4-thiazolidinedione has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tabatabaei Dakhili, SA | 1 |
| Pérez, DJ | 1 |
| Gopal, K | 1 |
| Haque, M | 1 |
| Ussher, JR | 1 |
| Kashfi, K | 1 |
| Velázquez-Martínez, CA | 1 |
1 other study available for 2,4-thiazolidinedione and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dr | 2021 |